Intellia Therapeutics Inc

NASDAQ:NTLA  
51.82
-2.60 (-4.78%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.91B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.57 Million
Adjusted EPS-$0.67
See more estimates
10-Day MA$58.15
50-Day MA$66.69
200-Day MA$36.06
See more pivots

Intellia Therapeutics, Inc. Stock, NASDAQ:NTLA

40 Erie Street, Suite 130, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.285.6200
Number of Employees: 270

Description

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.